MCHX vs CDLX vs PERI vs MGNI

For growth investors, Magnite, Inc.

(MGNI) is the stronger pick with 6. 9% revenue growth year-over-year, versus -16. 2% for Cardlytics, Inc. (CDLX). Magnite, Inc. (MGNI) offers the better valuation at 14. 7x trailing P/E (13. 4x forward), making it the more compelling value choice. Analysts rate Perion Network Ltd. (PERI) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Perion Network Ltd.

is actually cheaper at 8. 9x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Perion Network Ltd.

(PERI) delivered a total return of -37. 2%, compared to -99. 2% for Cardlytics, Inc. (CDLX). Over 10 years, the gap is even starker: PERI returned +139. 6% versus CDLX's -94. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Marchex, Inc.

(MCHX) is the lower-risk stock at 0. 87β versus Cardlytics, Inc. 's 3. 18β — meaning CDLX is approximately 266% more volatile than MCHX relative to the S&P 500. On balance sheet safety, Marchex, Inc. (MCHX) carries a lower debt/equity ratio of 4% versus 30% for Magnite, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Magnite, Inc.

(MGNI) is pulling ahead at 6. 9% versus -16. 2% for Cardlytics, Inc. (CDLX). On earnings-per-share growth, the picture is similar: Magnite, Inc. grew EPS 493. 8% year-over-year, compared to -176. 0% for Perion Network Ltd.. Over a 3-year CAGR, MGNI leads at 7. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Magnite, Inc.

(MGNI) is the more profitable company, earning 20. 3% net margin versus -44. 4% for Cardlytics, Inc. — meaning it keeps 20. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MGNI leads at 13. 7% versus -20. 2% for CDLX. At the gross margin level — before operating expenses — MCHX leads at 64. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Perion Network Ltd.

(PERI) trades at 8. 9x forward P/E versus 13. 4x for Magnite, Inc. — 4. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PERI: 29. 9% to $14. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Perion Network Ltd.

(PERI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), +139. 6% 10Y return). Cardlytics, Inc. (CDLX) carries a higher beta of 3. 18 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PERI: +139. 6%, CDLX: -94. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Communication Services sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: MCHX is a small-cap quality compounder stock; CDLX is a small-cap quality compounder stock; PERI is a small-cap quality compounder stock; MGNI is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.